miRNA Classifier for Lung Cancer Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for lung cancer detection, such as low-dose computed tomography, suffer from high false positive rates and significant costs, and there is a need for improved methodologies to predict, diagnose, and manage lung cancer effectively, especially for early-stage detection.
Innovation Solution
A method utilizing circulating miRNA biomarkers to determine the risk of developing or having a pulmonary tumor through a three-level classifier system, which assesses the expression ratios of specific miRNA pairs in biological samples, categorizing subjects as low, intermediate, or high risk based on positive or negative scores compared to cut-off values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If low-dose computed tomography (LDCT) screening is used for lung cancer detection, then detection sensitivity is improved, but false positive rate increases and cost increases
Solution Approach 1:
The invention segments the screening process into two distinct stages: (1) a first classifier using a limited set of miRNA expression ratios to perform initial risk stratification, and (2) a second classifier using an expanded set of miRNA expression ratios to confirm diagnosis. This segmentation allows the system to achieve high sensitivity in the first stage while maintaining high specificity in the second stage, thereby reducing false positives compared to using a single comprehensive test like LDCT.
Solution Approach 2:
The invention adds a new dimension to lung cancer screening by incorporating molecular biomarker analysis (miRNA expression profiles) as a complementary approach to anatomical imaging (LDCT). This multi-dimensional screening strategy enables the system to identify high-risk individuals through molecular signatures before anatomical changes become detectable, improving early detection while reducing unnecessary imaging procedures.
2Measurement precision
If low-dose computed tomography (LDCT) screening is used for lung cancer detection, then detection sensitivity is improved, but cost increases
Solution Approach 1:
The screening population is segmented into low-risk and high-risk groups based on miRNA expression profiles. Only high-risk individuals proceed to LDCT confirmation, while low-risk individuals are managed with surveillance. This segmentation dramatically reduces the number of expensive LDCT scans performed, lowering overall screening costs while maintaining high detection sensitivity for the population at greatest risk.
Solution Approach 2:
The miRNA-based classifier serves as a preliminary screening tool that identifies high-risk individuals before they undergo expensive LDCT scanning. By performing this molecular assessment first, the system pre-screens the population and directs resources efficiently, avoiding unnecessary costly imaging in low-risk individuals while ensuring thorough evaluation of high-risk cases.
3Loss of time
If traditional screening methods are used, then early detection capability is limited, but invasive procedures are reduced
Solution Approach 1:
The invention introduces miRNA expression analysis as an intermediary non-invasive test between routine screening and invasive diagnostic procedures. This molecular mediator provides early detection capability by identifying high-risk individuals through blood-based biomarkers, allowing clinicians to target invasive procedures (such as biopsies or surgical interventions) only to those who truly need them, thereby reducing overall invasiveness while improving early detection timing.
Data Source
AI summary
The present invention provides a method of determining the presence of a pulmonary tumor in a subject is provided. Also provided is a method of determining the presence of an aggressive pulmonary tumor in a subject. Additionally, a method of determining the risk of manifesting a pulmonary tumor in a subject is provided. Further provided is a method of determining the risk of manifesting an aggressive pulmonary tumor in a subject. A method for predicting the risk of developing or having a pulmonary tumor in a subject is also provided. A method of establishing lung cancer treatment options is additionally provided.